What To Consider For A Modular Facility With Closed Processing

By Sarah Le Merdy, Alejandro Kaiser, PE, Jérome Dalin And JP Bornholdt, AIA, PE, LEED AP

The biopharmaceutical industry is trending toward new product classes and smaller batch sizes which is driving an even greater need for modular facilities and closed processing, especially for product lines that cannot undergo sterile filtration before administration to patients. This advanced approach to facility design and manufacturing yields a wide range of benefits, including increased flexibility, speed, and quality. Additionally, it leads to life-cycle cost savings attributed to improved operational risk mitigation, reduced environmental controls, and enhanced operational efficiencies.

The advantages of modular facilities and closed processing are gaining significance in light of the growing number of therapeutic classes, which is driving the demand for the establishment of multi-product and multi-modal facilities. Facilities of the future will be able to manufacture a variety of products across different therapeutic classes to maximize facility and asset utilization. This marks a departure from the historical approach of designing manufacturing plants tailored to a single product. Learn more about the progression toward closed processing and how to position your organization for success.